Psychiatry/Psychology | Phase II Developments | UNITED STATES

American BriVision

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

American BriVision First Patient Enrolled for Phase II Part I Clinical Trial for ABV-1505

Lead Product(s): PDC-1421

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 04, 2020

Details:

First of six patients has been enrolled for Phase II Part I trial of ABV-1505 at the University of California, San Francisco (UCSF) Medical Center.

VistaGen Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10

Lead Product(s): PH10

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 20, 2020

Details:

PH10, demonstrated significant rapid-onset antidepressive benefit versus placebo, without psychological side effects or safety concerns often associated with Ketamine-based Therapy.

BlackThorn Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders

Lead Product(s): BTRX-140

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2020

Details:

The Phase 2 proof-of-concept trial is designed to evaluate the efficacy, safety and tolerability of BTRX-140 in approximately 120 patients with major depressive disorder.

Seelos Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Seelos Therapeutics releases interim study data validating the safety of its ketamine depression drug

Lead Product(s): Ketamine Hydrochloride,Venlafaxine,Sertraline Hydrochloride

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

It showed 60 milligrams of SLS-002 to be safe and well tolerated as a monotherapy or with an oral antidepressant.

Newron Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Newron Announces Initiation of New Clinical Trial With Evenamide in Patients With Schizophrenia, Following Approval of Plan By FDA

Lead Product(s): NW-3509

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

FDA approved the plan proposed by Newron as well as the protocol for a first, four-week explanatory study in patients with schizophrenia, expected to start enrolling patients in the next few days.

Find

Find Psychiatry/Psychology Drugs in Phase II Clinical Development in UNITED STATES

United States

A collaboration with SCORR Marketing

Product Type

Companies

American BriVision

American BriVision First Patient Enrolled for Phase II Part I Clinical Trial for ABV-1505

VistaGen Therapeutics

VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10

BlackThorn Therapeutics

BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders

Seelos Therapeutics

Seelos Therapeutics releases interim study data validating the safety of its ketamine depression drug

Newron Pharmaceuticals

Newron Announces Initiation of New Clinical Trial With Evenamide in Patients With Schizophrenia, Following Approval of Plan By FDA